Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest diabetic neuropathy Stories

2009-12-09 06:00:00

RICHMOND, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany. The preliminary data were from the first subjects enrolled in Sangamo's Phase 2 clinical trial,...

2009-11-18 07:00:00

WALTHAM, Mass., Nov. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of therapies to treat diabetic retinopathy, diabetic neuropathy and diabetic nephropathy will increase by more than 70 percent from $3.2 billion in 2008 to $5.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Diabetic Retinopathy,...

2009-11-09 11:22:00

Neurologists will use funds to move lab findings into human therapy for difficult-to-treat condition that involves pain from nerve damage ANN ARBOR, Mich., Nov. 9 /PRNewswire-USNewswire/ --Researchers from the University of Michigan Department of Neurology have received a $1.8 million grant to develop a novel therapy for neuropathic pain, a difficult-to-treat condition in which patients experience pain because of damage to nerve without obvious tissue injury. In previously published...

2009-10-30 07:30:00

SAN MATEO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, November 6, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its third quarter 2009. The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer. To...

2009-10-27 14:36:36

HealthCore study shows Metanx also reduces health plan costs Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress. The results of the HealthCore, Inc. study, funded by Pamlab, L.L.C., which manufactures the medical food...

2009-10-27 01:00:00

PARIS, Oct. 27 /PRNewswire/ -- Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress. The results of the HealthCore, Inc. study, funded by Pamlab, L.L.C., which manufactures the medical food Metanx®,...

2009-10-20 13:00:00

RICHMOND, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of top-line, statistically significant Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the Society for Neuroscience Annual Meeting held in Chicago. Top-line data from Sangamo's SB-509-601 Phase 2 clinical trial demonstrated a direct neuroregenerative effect of SB-509 treatment that...

2009-10-01 10:12:00

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs. A new, federally-funded study by Queen's University researchers has found that taking the drugs together is a more effective treatment than taking either of them individually. When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain...

2009-09-22 12:17:00

NEW YORK, Sept. 22 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program. Every year, The Neuropathy Association--the leading national non-profit organization dedicated to finding cures for peripheral neuropathies--awards two scientific research grants, each for $80,000 over a two-year period. This year's grant recipients--Dennis Paul, Ph.D. and co-principal investigator, Harry J. Gould, M.D., Ph.D. of Louisiana...

2009-09-17 15:01:00

SAN MATEO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference, to be held September 21 - 23, 2009 in New York City. Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to...